about
Cognitive-motor dual-task interference: A systematic review of neural correlates.The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory.Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD)Offspring Number Does Not Influence Reaching the Disability's Milestones in Multiple Sclerosis: A Seven-Year Follow-Up Study.Treatment options of cognitive impairment in multiple sclerosis.Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal.Association Between Dietary Intake and Function in Amyotrophic Lateral Sclerosis.Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis.Prevalence of patient-reported dysphagia in multiple sclerosis patients: an Italian multicenter study (using the DYMUS questionnaire).Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide.The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study.Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience.Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis opticaThe DYMUS questionnaire for the assessment of dysphagia in multiple sclerosisFrequency and severity of headache is worsened by Interferon-β therapy in patients with multiple sclerosisThe Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple SclerosisPharmacoeconomics of synthetic therapies for multiple sclerosisReview: Patient-reported outcomes in multiple sclerosis careImmunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatmentPharmacotherapeutic management of lower urinary tract symptomsDimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis
P50
Q30572205-4B831629-9CA7-4408-A7EE-E16D47A6BE00Q36062456-5BEDDB1F-7BF5-4BF5-9A25-CE0FEBC23AAAQ36134388-739AC19F-7933-4703-9FB5-529FD971D432Q36484548-690B2165-A01D-49AE-B685-E526EA68537AQ36667149-553EEE5D-847D-4F82-81A8-ED9FC7B86901Q37800836-2AAA5D2E-E429-4AEC-B8AB-727A4C3CDB42Q38364547-BAFD2AD2-362F-4FBC-A49C-D0C9D3B66896Q38397484-B6DF92AB-0BF6-4E9F-AD50-EF29E0BB66C1Q38534132-301B5632-8519-46F4-8419-C80363CFEED8Q38752155-01EDBFAF-85CC-4BAC-9022-52CAD3809242Q39254848-13F74F9B-6ACB-4273-94D4-3E4BA04B4CA3Q43857891-AEDF6DAE-BE01-4AC9-81E3-D9F42EB96865Q44157548-79763D7C-0F07-4A4A-81A3-F2125C7A8284Q45937438-84B590FC-A653-4ABD-A735-D14CC696157AQ47592467-50FDC2D7-F543-4B68-A9A5-2A5312311423Q52665179-54C30767-D832-4DF5-9523-DBFEF3047383Q59389218-6D9A5262-ECF3-48CF-99FB-2F6AC4D6CC31Q61718805-C26F1FAD-0B10-46F4-BF18-EAF815CC1FC7Q84295095-F06EFA13-915A-498F-A352-F7E0573EA33FQ90227528-50444C95-803D-4724-9D66-A29EF392DE80Q92032664-02EF588F-BB52-47F4-8D09-467FBF041793Q92465072-34D88E95-11DA-4780-B3A7-D3E962797F97Q92868640-91AFC727-5D4A-40A1-A36C-63EEC1675C8AQ95840454-6D4B24B8-3504-4D74-B875-94A4305AD7EEQ96162516-BE9B4276-6A2B-4013-9397-2D2DC595F228
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Emanuele D'Amico
@ast
Emanuele D'Amico
@en
Emanuele D'Amico
@es
Emanuele D'Amico
@sl
type
label
Emanuele D'Amico
@ast
Emanuele D'Amico
@en
Emanuele D'Amico
@es
Emanuele D'Amico
@sl
prefLabel
Emanuele D'Amico
@ast
Emanuele D'Amico
@en
Emanuele D'Amico
@es
Emanuele D'Amico
@sl
P1053
C-3752-2011
P106
P1153
55412854000
P21
P31
P3829
P496
0000-0001-7494-9057
P569
2000-01-01T00:00:00Z